12:00 AM
Jan 26, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Apo2L/TRAIL: Completed Phase II enrollment

Last quarter, the partners completed enrollment of 213 patients in a 5-arm, open-label Phase II trial evaluating chemotherapy (carboplatin and paclitaxel) alone, chemotherapy plus 8 mg/kg AMG 951, chemotherapy plus Avastin, or chemotherapy plus Avastin and...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >